Page 61 - Pharma

Lupin receives US FDA approval for arthritis drug

The company has received marketing approval for Celecoxib, a generic version of GD Searle LLC's (a subsidiary of Pfizer Inc) Celebrex capsules

Lonza and Bristol-Myers Squibb expand manufacturing pact for biologics

With this, Lonza's mammalian manufacturing facility in Portsmouth, New Hampshire, will manufacture commercial quantities of a second Bristol-Myers Squibb biologics

Biocon expands partnership with US-based CytoSorbents

Two companies have expanded the scope of their strategic partnership for CytoSorbents' CytoSorb, a critical care drug

Alembic's formulation plant in Sikkim to be operational this fiscal

The Vadodara-based pharma company is reportedly investing Rs 100 crore in the new plant, which will have a capacity of 2.5 billion tablets and capsules

Ranbaxy Labs swings back to profit

The company posts net profit of Rs 478 cr in Q2 of 2014-15 compared to last year's loss of Rs 454 cr driven mainly due to exclusivity sales of Valsartan in the US during the quarter

Harsh Vardhan to urge global experts to unite for fighting TB

During his visit to Spain, India is expected to sign an MoU with Spain on organ transplant knowhow transfer

CCI imposes Rs 10 lakh fine on Goa's chemist association

The Competition Commission of India found that CDAG was indulging in anti-competitive practices by controlling the supply chain through which drugs and medicines are supplied

Thermo Fisher Scientific opens manufacturing facility in California

The $85-mn facility will develop and manufacture innovative technologies for diagnostic testing and quality controls that have applications in healthcare and other markets

Alembic forms JV with Adwiya Mami to enter Algerian market

The Vadodara-based company has picked 49% stake in Adwiya Mami

India needs to step up medical research: Narendra Modi

While addressing convocation ceremony of AIIMS, PM urged the young graduates to keep the student mindset in alive

Govt to organise World Ayurveda Congress in November

All India Institute of Ayurveda (AIIA) coming up at Jasola, Delhi, will emerge as a Centre of Excellence dealing with fundamental research, drug safety evaluation, standardisation, etc of Ayurveda med

Natco receives USFDA tentative approval for armodafinil tablets

The company and its US partner, Breckenridge, have a license to market generic versions of Nuvigil (armodafinil) with 180 days exclusivity period

Alembic Pharma's Q2 profit up 25% at Rs 77.27 cr

The company has reported 31 per cent growth in net profit for first half of the year at Rs 141.9 crore

Cadila Healthcare recalls 5,400 bottles of Atenolol tablets in US

The company has initiated the recall, as a complaint was reported by a pharmacist who stated several tablets were noticeably thicker in appearance, says USFDA

UK MHRA inspects Sharon Bio-Medicine's plant in Uttarakhand

A team from the UK drug regulator conducted inspection for GMP at the company's recently expanded formulation plant in Uttarakhand

Abbott opens nutrition products facility in Gujarat

The company plans to locally source 80% of the raw material for the new plant's products. So far, the company was importing most of these from its Singapore and European facilities

Ranbaxy to pay Texas $40 mn to settle litigation

The claims at issue related exclusively to the manner in which the Ranbaxy has historically reported pricing data to Texas Medicaid for certain of its drugs

Novartis receives NPPA notice imposing Rs 300-cr penalty for overcharging

Drug regulator has slapped the notice on Swiss drug maker for overcharging consumers on sale of its pain-killer drug Voveran

Suven Life Sciences secures patents for CNS drug in US and South Korea

The company was granted patents, which are valid through 2030, for a new chemical entity used in the treatment of disorders associated with neurodegenerative diseases

US Congress initiate probe against Sun Pharma, Dr Reddy's, Cadila

These three Indian pharma majors are among 14 companies being investigated for skyrocketing prices of ten generic drugs